MX2019004463A - Formulacion oftalmica que comprende citicolina transportada por liposomas para el tratamiento del glaucoma. - Google Patents

Formulacion oftalmica que comprende citicolina transportada por liposomas para el tratamiento del glaucoma.

Info

Publication number
MX2019004463A
MX2019004463A MX2019004463A MX2019004463A MX2019004463A MX 2019004463 A MX2019004463 A MX 2019004463A MX 2019004463 A MX2019004463 A MX 2019004463A MX 2019004463 A MX2019004463 A MX 2019004463A MX 2019004463 A MX2019004463 A MX 2019004463A
Authority
MX
Mexico
Prior art keywords
citicoline
glaucoma
ophthalmic formulation
liposome
treatment
Prior art date
Application number
MX2019004463A
Other languages
English (en)
Inventor
Virno Cristiano
MALIZIA Marco
Original Assignee
Omikron Italia S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omikron Italia S R L filed Critical Omikron Italia S R L
Publication of MX2019004463A publication Critical patent/MX2019004463A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención está relacionada con una formulación oftálmica que comprende citicolina y liposomas para ser usada en el tratamiento del glaucoma. Los inventores han encontrado que los liposomas resultan ser particularmente eficaces para transportar la citicolina en el segmento posterior del ojo (cámara vítrea) y en alcanzar la retina y la cabeza del nervio óptico.
MX2019004463A 2016-10-17 2017-10-16 Formulacion oftalmica que comprende citicolina transportada por liposomas para el tratamiento del glaucoma. MX2019004463A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102016000103956A IT201600103956A1 (it) 2016-10-17 2016-10-17 Formulazione oftalmica comprendente citicolina veicolata da liposomi per il trattamento del glaucoma
PCT/IB2017/056400 WO2018073720A1 (en) 2016-10-17 2017-10-16 Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma

Publications (1)

Publication Number Publication Date
MX2019004463A true MX2019004463A (es) 2019-09-11

Family

ID=58010202

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004463A MX2019004463A (es) 2016-10-17 2017-10-16 Formulacion oftalmica que comprende citicolina transportada por liposomas para el tratamiento del glaucoma.

Country Status (8)

Country Link
US (1) US10576039B2 (es)
EP (1) EP3525758B1 (es)
JP (1) JP7042262B2 (es)
EA (1) EA201990752A1 (es)
IT (1) IT201600103956A1 (es)
MX (1) MX2019004463A (es)
TN (1) TN2019000112A1 (es)
WO (1) WO2018073720A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3412276A3 (de) 2017-06-09 2019-07-17 Omnivision GmbH Zusammensetzung zur behandlung des trockenen auges
IT201800005309A1 (it) * 2018-05-11 2019-11-11 Composizione ad attivita’ antimicrobica
CN110559261A (zh) * 2018-06-06 2019-12-13 常州药物研究所有限公司 含有纳米交联透明质酸的脂质体微乳及其制备方法和应用
CN111840220B (zh) * 2020-08-19 2022-09-30 开封康诺药业有限公司 一种胞磷胆碱钠注射液及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114577A1 (en) * 1983-01-21 1984-08-01 MAGIS FARMACEUTICI S.p.A. New pharmaceutical composition
JP2002034252A (ja) 2000-07-18 2002-01-31 Sony Corp スイッチング電源回路
CN102316852A (zh) 2009-02-11 2012-01-11 丽卡实验有限公司 脂质胞二磷胆碱注射液
IT1398378B1 (it) 2010-02-22 2013-02-22 Omikron Italia S R L Citicolina per il trattamento del glaucoma e dell'ipertensione oculare.
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
CN102078299B (zh) * 2011-01-04 2012-09-26 海南美大制药有限公司 胞磷胆碱钠脂质体固体制剂

Also Published As

Publication number Publication date
US20190321292A1 (en) 2019-10-24
EP3525758A1 (en) 2019-08-21
EP3525758B1 (en) 2024-05-22
US10576039B2 (en) 2020-03-03
EA201990752A1 (ru) 2019-09-30
JP7042262B2 (ja) 2022-03-25
IT201600103956A1 (it) 2018-04-17
TN2019000112A1 (en) 2020-10-05
WO2018073720A1 (en) 2018-04-26
JP2019530729A (ja) 2019-10-24

Similar Documents

Publication Publication Date Title
TN2019000112A1 (en) Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma
MX2017005204A (es) Dispositivos y métodos de estimulación para tratar el ojo seco.
MX2020011301A (es) Uso de clorhidrato de pilocarpina para el tratamiento de afecciones oculares.
EP3749264C0 (en) LASER THERAPY FOR TREATMENT AND PREVENTION OF EYE DISEASES
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
EA201790889A1 (ru) Офтальмологический раствор
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
MY199237A (en) Methods of treating ocular conditions
WO2018204903A3 (en) DEVICES AND METHODS FOR TREATING EYELIDS
WO2018136669A3 (en) Therapeutic and neuroprotective peptides
MX2022005063A (es) Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina.
IL273531A (en) Ophthalmic preparations containing latanoprost for use in the treatment of eye diseases
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
PT3413868T (pt) Composição oftálmica para utilização no tratamento de distúrbios oculares relacionados com alterações da superfície córneo-conjuntival
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX2021014000A (es) Formulaciones oftalmicas topicas de liposomas cargados con acetonido de triamcinolona para la prevencion del engrosamiento macular y sus resultados visuales asociados despues de la cirugia del cristalino.
TN2016000259A1 (en) Salbutamol (albuterol) eye protective medicament.
SG11202012473UA (en) Ophthalmic compositions and methods for the treatment of eye disorders
IL282898A (en) Ophthalmic compounds and methods for treating skin and eye diseases
CR20170346A (es) Composiciones para el tratamiento de infecciones producidas por el ácaro demodex spp
AR110947A1 (es) Tratamiento de degeneración de la retina mediante el uso de células progenitoras
IL280588A (en) Ophthalmic compositions and methods for treating eye problems and skin diseases
TW201613596A (en) Ophthalmic suspension preparation
EA202192183A1 (ru) Композиции, обладающие активностью удаления липофусцина из клеток сетчатки
MX2016006256A (es) Tratamiento de glaucoma usando laquinimod.